top of page

NETPark business seeks £25m to advance motor neurone disease treatment

45 minutes ago
1 min read

Nevrargenics Chief executive Professor Andy Whiting (Image credit Durham University)
Nevrargenics Chief executive Professor Andy Whiting (Image credit Durham University)

NETPark-based Nevrargenics is seeking £25 million in investment to take its lead drug candidate into human trials, marking a potential next step for research originating at Durham University.


The university spin-out is raising Series A funding to support a proposed clinical trial in Australia and five years of further development.


The planned trial would investigate Ellorarxine in people with amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease. The compound is being developed to explore its potential to protect or repair nerve cells damaged by disease.


Chief executive Professor Andy Whiting says the company’s preclinical work is complete. Ellorarxine has not yet been tested in people, and the proposed trial depends on securing investment.


The funding would also support the development of further drug candidates targeting other neurodegenerative diseases.


Based at NETPark in Sedgefield, Nevrargenics forms part of a community bringing together university research, specialist expertise and science and technology businesses.

Other Science, engineering & technology news

bottom of page